Kiniksa Pharmaceuticals International, plc stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Kiniksa Pharmaceuticals International, plc stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Kiniksa Pharmaceuticals International, plc do? Business model and key facts
Get the full picture of Kiniksa Pharmaceuticals International, plc: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Employees (FY): 366
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Stocks related to Kiniksa Pharmaceuticals International, plc
Selected based on industry alignment and relative market positioning.
Events and news impacting Kiniksa Pharmaceuticals International, plc stock
Earnings, coporate decisions and industry developments that can affect the share price.
Kiniksa Pharmaceuticals International, plc fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
